<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DC90A2BE-C009-482F-BD40-FA2EF60F8C63"><gtr:id>DC90A2BE-C009-482F-BD40-FA2EF60F8C63</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Aylott</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FN009126%2F1"><gtr:id>787CB2FD-9E9F-4ABF-9BA0-3063D727FAF2</gtr:id><gtr:title>Foresight Fellowship in Manufacturing: Analytical technologies in continuous and additive manufacturing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>EP/N009126/1</gtr:grantReference><gtr:abstractText>This Fellowship application seeks to accelerate the uptake of continuous and additive manufacturing in the pharmaceutical industry. Continuous manufacturing is widely used in many sectors, where just-in-time protocols are common. Additive manufacturing, encompassing 3D-printing, has received much attention recently as printers have become commercially available. Additive manufacturing is a very flexible process and is currently used predominantly for prototype manufacture, enabling personalisation of products. However, scaling-up additive manufacturing processes is challenging and the vision of scales-out (multiple printers or print heads) is often suggested. In contrast, continuous manufacturing processes offer a more direct route to scale-up and are also flexible; the same production line can be used to manufacture a number of different products. However quality assurance protocols in continuous manufacturing are challenging.

Many reasons are given for the pharmaceutical industry not adopting the latest manufacturing technologies, chief among these are regulatory concerns. This is in part due to innate conservatism from the regulators (though the FDA is encouraging change) but also due to a lack of analytical technologies being integrated with the continuous manufacturing production lines to ensure product quality. It is these analytical challenges that this Fellowship seeks to address.</gtr:abstractText><gtr:potentialImpactText>Society needs better medicines, produced on a cost efficient basis. To achieve this the pharmaceutical industry needs to implement the latest scientific and technological advances. The model of manufacturing in the pharmaceutical industry has not innovated in recent times and significant benefits will arise in terms of product flexibility and stratification if current state-of-the-art manufacturing capability is developed.
Addressing this challenge will lead to society as a whole benefiting as new medicines reach the market. The pharmaceutical industry will benefit as it is able to take a more flexible approach to manufacturing, improving efficiencies and reducing costs. 

The integration of analytical technologies into continuous and additive manufacturing processes is likely to generate IP and so there will be benefits to the University and industry from exploiting the IP. There will be academic benefit from crossing disciplinary boundaries and also from working cross-sector.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2015-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>132415</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>369000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Future Targeted Healthcare Manufacturing Hub</gtr:description><gtr:end>2024-12-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/P006485/1</gtr:fundingRef><gtr:id>9EEB90FE-29E5-4592-8D89-90096C9FE93D</gtr:id><gtr:outcomeId>58c7c80d7d16f8.77720938</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">EP/N009126/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>863FC58A-7217-42EA-B076-663F2D770BB8</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Chemical measurement</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FA25733D-A456-4A1B-9D5C-7119577368D9</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Manufacturing</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>98EA7556-1427-44F9-84F3-BF99B7207302</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Analytical Science</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>ABBD3B7F-5022-4513-82D6-5414B965FAB3</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Manufacturing Machine &amp; Plant</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>